Related references
Note: Only part of the references are listed.Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Nancy Y Lee et al.
LANCET ONCOLOGY (2021)
Clinical significance of peripheral blood and tumor tissue lymphocyte subsets in cervical cancer patients
Yutuan Wu et al.
BMC CANCER (2020)
TIGIT as an emerging immune checkpoint
H. Harjunpaa et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment
Lien Lippens et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer
Jyoti Mayadev et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy
Takaaki Tsuchiya et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2020)
Radiation-induced lymphopenia: the main aspects to consider in immunotherapy trials for endometrial and cervical cancer patients
K. Holub et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Hiro Sato et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)
Advances in immunotherapy for cervical cancer
R. Wendel Naumann et al.
CURRENT OPINION IN ONCOLOGY (2020)
Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
Linda R. Duska et al.
CANCER (2020)
Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)
Diane M. Da Silva et al.
CLINICAL CANCER RESEARCH (2020)
On the Immunological Consequences of Conventionally Fractionated Radiotherapy
Juan Carlos L. Alfonso et al.
ISCIENCE (2020)
Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma
Moito Iijima et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2020)
Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
Larissa Lee et al.
GYNECOLOGIC ONCOLOGY (2019)
Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis
Andrew M. Frederickson et al.
IMMUNOTHERAPY (2019)
Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial
Willemijn S. M. E. Theelen et al.
JAMA ONCOLOGY (2019)
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
Mathieu Grapin et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer
Kazue Yoneda et al.
BRITISH JOURNAL OF CANCER (2019)
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial
R. Wendel Naumann et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Rational combinations of immunotherapy with radiotherapy in ovarian cancer
Fernando G. Herrera et al.
LANCET ONCOLOGY (2019)
Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors
Si Yang et al.
ONCOIMMUNOLOGY (2019)
Revised FIGO staging for carcinoma of the cervix uteri
Neerja Bhatla et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2019)
Letter to the editor, Reply to: Lee and Matulonis: Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
Bradley J. Monk et al.
GYNECOLOGIC ONCOLOGY REPORTS (2019)
Prior irradiation results in elevated programmed cell death protein 1 (PD-1) in T cells
Deguan Li et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Silvia C. Formenti et al.
NATURE MEDICINE (2018)
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms
T. Kordbacheh et al.
ANNALS OF ONCOLOGY (2018)
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
Jean-Sebastien Frenel et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
Oscar Arrieta et al.
ONCOTARGET (2017)
Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients
Daichi Fujimoto et al.
SCIENTIFIC REPORTS (2017)
Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients
H. van Meir et al.
ONCOIMMUNOLOGY (2017)
An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers
Antoine Hollebecque et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab for previously treated advanced cervical squamous cell cancer: Preliminary results from the phase 2 KEYNOTE-158 study
Jan H. M. Schellens et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer
Grit S. Herter-Sprie et al.
JCI INSIGHT (2016)
Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes
Patrick H. Lizotte et al.
JCI INSIGHT (2016)
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Extended field chemoradiation for cervical cancer patients with histologically proven para-aortic lymph node metastases after laparaoscopic lymphadenectomy
Simone Marnitz et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2015)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
FIGO Cancer Report 2012
Lynette Denny et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2012)
Severe Late Toxicities Following Concomitant Chemoradiotherapy Compared to Radiotherapy Alone in Cervical Cancer: An Inter-era Analysis
Vinai Gondi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix
Alfonso Duenas-Gonzalez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Low density of CD3+, CD4+ and CD8+ cells is associated with increased risk of relapse in squamous cell cervical cancer
B. S. Nedergaard et al.
BRITISH JOURNAL OF CANCER (2007)
CD4+CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia
Johan W. Molling et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Peripheral blood lymphocyte subpopulations in patients with cervical cancer
S. Das et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2007)
Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: A gynecologic oncology group study
Peter G. Rose et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
High number of intraepithelial CD8(+) tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer
Sytse J. Piersma et al.
CANCER RESEARCH (2007)
Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix
Sylvain Monnier-Benoit et al.
GYNECOLOGIC ONCOLOGY (2006)
T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia
JC Steele et al.
BRITISH JOURNAL OF CANCER (2005)
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) 90-01
PJ Eifel et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis
JA Green et al.
LANCET (2001)
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix
WA Peters et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
